Expertise in
10
conditions

Peter R. Lang

Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
10
conditions
Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 

Overview

Peter Lang practices practicing medicine in Tuebingen, Germany.

Mr. Lang is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Neuroblastoma, Metachromatic Leukodystrophy, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 186 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Enrollment Status: Recruiting
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Drug
Study Drug: ch14.18/CHO
Study Phase: Phase 2
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Enrollment Status: Terminated
Publish Date: October 21, 2022
Intervention Type: Procedure
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

186 Total Publications

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.
Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.
Journal: American journal of hematology
Published: May 14, 2026

Frequently Asked Questions about Peter R. Lang

Is Peter R. Lang a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Peter R. Lang is classified as an Distinguished expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Peter R. Lang participate in research or clinical trials?

Yes. Peter R. Lang has published 186 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Peter R. Lang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lang's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile